In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Milestone Scientific (NYSE: MLSS), with a price target of $3. The company’s shares opened today at $0.70, close to its 52-week low of $0.64.
“Yesterday, after the Market close, MLSS reported lower-than-expected 1Q18 revenue and GAAP EPS, primarily due to an inventory build-up in its exclusive US dental distributor, Henry Schein (HSIC – NR).”
According to TipRanks.com, Vendetti is ranked #609 out of 4800 analysts.
Milestone Scientific has an analyst consensus of Moderate Buy, with a price target consensus of $4.
The company has a one-year high of $1.80 and a one-year low of $0.64. Currently, Milestone Scientific has an average volume of 32.14K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Milestone Scientific, Inc. engages in the provision of pioneering proprietary, innovative technological systems and solutions. It also involves in the development, manufacture, market, and selling of computer controlled system for the improved and painless delivery of local anesthetic. It operates through the Dental and Medical segments.